Genistein induces G2/M cell cycle arrest and apoptosis via ATM/p53-dependent pathway in human colon cancer cells

Zhang,Zhiyu; Wang,Chong-Zhi; Du,Guang-Jian; Qi,Lian-Wen; Calway,Tyler; He,Tong-Chuan; Du,Wei; Yuan,Chun-Su

doi:10.3892/ijo.2013.1946

Genistein induces G2/M cell cycle arrest and apoptosis via ATM/p53-dependent pathway in human colon cancer cells

Authors:
- Zhiyu Zhang
- Chong-Zhi Wang
- Guang-Jian Du
- Lian-Wen Qi
- Tyler Calway
- Tong-Chuan He
- Wei Du
- Chun-Su Yuan
View Affiliations

Affiliations: Tang Center for Herbal Medicine Research, University of Chicago, Chicago, IL 60637, USA, Department of Anesthesia and Critical Care, University of Chicago, Chicago, IL 60637, USA, Department of Surgery, University of Chicago, Chicago, IL 60637, USA, Ben May Department for Cancer Research, University of Chicago, Chicago, IL 60637, USA
Published online on: May 17, 2013 https://doi.org/10.3892/ijo.2013.1946
Pages: 289-296

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Soybean isoflavones have been used as a potential preventive agent in anticancer research for many years. Genistein is one of the most active flavonoids in soybeans. Accumulating evidence suggests that genistein alters a variety of biological processes in estrogen-related malignancies, such as breast and prostate cancers. However, the molecular mechanism of genistein in the prevention of human colon cancer remains unclear. Here we attempted to elucidate the anticarcinogenic mechanism of genistein in human colon cancer cells. First we evaluated the growth inhibitory effect of genistein and two other isoflavones, daidzein and biochanin A, on HCT-116 and SW-480 human colon cancer cells. In addition, flow cytometry was performed to observe the morphological changes in HCT-116/SW-480 cells undergoing apoptosis or cell cycle arrest, which had been visualized using Annexin V-FITC and/or propidium iodide staining. Real-time PCR and western blot analyses were also employed to study the changes in expression of several important genes associated with cell cycle regulation. Our data showed that genistein, daidzein and biochanin A exhibited growth inhibitory effects on HCT-116/SW-480 colon cancer cells and promoted apoptosis. Genistein showed a significantly greater effect than the other two compounds, in a time- and dose-dependent manner. In addition, genistein caused cell cycle arrest in the G2/M phase, which was accompanied by activation of ATM/p53, p21waf1/cip1 and GADD45α as well as downregulation of cdc2 and cdc25A demonstrated by q-PCR and immunoblotting assay. Interestingly, genistein induced G2/M cell cycle arrest in a p53-dependent manner. These findings exemplify that isoflavones, especially genistein, could promote colon cancer cell growth inhibition and facilitate apoptosis and cell cycle arrest in the G2/M phase. The ATM/p53-p21 cross-regulatory network may play a crucial role in mediating the anticarcinogenic activities of genistein in colon cancer.

View Figures

View References

1.	Arber N and Levin B: Chemoprevention of colorectal cancer: ready for routine use? Recent Results Cancer Res. 166:213–230. 2005. View Article : Google Scholar : PubMed/NCBI
2.	Rodriguez M, Du GJ, Wang CZ and Yuan CS: Letter to the editor: Panaxadiol’s anticancer activity is enhanced by epicatechin. Am J Chin Med. 38:1233–1235. 2010.PubMed/NCBI
3.	Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar
4.	Wils J, O’Dwyer P and Labianca R: Adjuvant treatment of colorectal cancer at the turn of the century: European and US perspectives. Ann Oncol. 12:13–22. 2001. View Article : Google Scholar : PubMed/NCBI
5.	Segal NH and Saltz LB: Evolving treatment of advanced colon cancer. Annu Rev Med. 60:207–219. 2009. View Article : Google Scholar
6.	Thomasset SC, Berry DP, Garcea G, Marczylo T, Steward WP and Gescher AJ: Dietary polyphenolic phytochemicals - promising cancer chemopreventive agents in humans? A review of their clinical properties. Int J Cancer. 120:451–458. 2007. View Article : Google Scholar
7.	Doll R and Peto R: The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst. 66:1191–1308. 1981.PubMed/NCBI
8.	Umthong S, Puthong S and Chanchao C: Trigona laeviceps propolis from Thailand: antimicrobial, antiproliferative and cytotoxic activities. Am J Chin Med. 37:855–865. 2009. View Article : Google Scholar : PubMed/NCBI
9.	Fournier DB, Erdman JW Jr and Gordon GB: Soy, its components and cancer prevention: a review of the in vitro, animal and human data. Cancer Epidemiol Biomarkers Prev. 7:1055–1065. 1998.PubMed/NCBI
10.	Kao TH, Chien JT and Chen BH: Extraction yield of isoflavones from soybean cake as affected by sovlent and supercritical carbon dioxide. Food Chem. 107:1728–1736. 2008. View Article : Google Scholar
11.	Banerjee S, Li Y, Wang Z and Sarkar FH: Multi-targeted therapy of cancer by genistein. Cancer Lett. 269:226–242. 2008. View Article : Google Scholar : PubMed/NCBI
12.	Hartwell LH and Kastan MB: Cell cycle control and cancer. Science. 266:1821–1828. 1994. View Article : Google Scholar : PubMed/NCBI
13.	Igney FH and Krammer PH: Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2:277–288. 2002. View Article : Google Scholar : PubMed/NCBI
14.	Agarwal MK, Hastak K, Jackson MW, Breit SN, Stark GR and Agarwal ML: Macrophage inhibitory cytokine 1 mediates a p53-dependent protective arrest in S phase in response to starvation for DNA precursors. Proc Natl Acad Sci USA. 103:16278–16283. 2006. View Article : Google Scholar : PubMed/NCBI
15.	Liu BP, Chong EY, Cheung FW, Duan JA, Che CT and Liu WK: Tangutorine induces p21 expression and abnormal mitosis in human colon cancer HT-29 cells. Biochem Pharmacol. 70:287–299. 2005. View Article : Google Scholar : PubMed/NCBI
16.	Taylor CK, Levy RM, Elliott JC and Burnett BP: The effect of genistein aglycone on cancer and cancer risk: a review of in vitro, preclinical and clinical studies. Nutr Rev. 67:398–415. 2009. View Article : Google Scholar : PubMed/NCBI
17.	Schleipen B, Hertrampf T, Fritzemeier KH, et al: ERbeta-specific agonists and genistein inhibit proliferation and induce apoptosis in the large and small intestine. Carcinogenesis. 32:1675–1683. 2011. View Article : Google Scholar : PubMed/NCBI
18.	Vousden KH and Lane DP: p53 in health and disease. Nat Rev Mol Cell Biol. 8:275–283. 2007. View Article : Google Scholar
19.	Luo X, Chen J, Song WX, et al: Osteogenic BMPs promote tumor growth of human osteosarcomas that harbor differentiation defects. Lab Invest. 88:1264–1277. 2008. View Article : Google Scholar : PubMed/NCBI
20.	Kim EJ, Shin HK and Park JH: Genistein inhibits insulin-like growth factor-I receptor signaling in HT-29 human colon cancer cells: a possible mechanism of the growth inhibitory effect of Genistein. J Med Food. 8:431–438. 2005. View Article : Google Scholar
21.	Meloche S and Pouyssegur J: The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene. 26:3227–3239. 2007. View Article : Google Scholar : PubMed/NCBI
22.	Yu ZL, Li WJ and Liu FY: Inhibition of proliferation and induction of apoptosis by genistein in colon cancer HT-29 cells. Cancer Lett. 215:159–166. 2004. View Article : Google Scholar : PubMed/NCBI
23.	Park JH, Oh EJ, Choi YH, et al: Synergistic effects of dexamethasone and genistein on the expression of Cdk inhibitor p21(WAF1/CIP1) in human hepatocellular and colorectal carcinoma cells. Int J Oncol. 18:997–1002. 2001.PubMed/NCBI
24.	Vousden KH and Lu X: Live or let die: the cell’s response to p53. Nat Rev Cancer. 2:594–604. 2002.
25.	Qi W, Weber CR, Wasland K and Savkovic SD: Genistein inhibits proliferation of colon cancer cells by attenuating a negative effect of epidermal growth factor on tumor suppressor FOXO3 activity. BMC Cancer. 11:2192011. View Article : Google Scholar : PubMed/NCBI
26.	Zhou BB and Elledge SJ: The DNA damage response: putting checkpoints in perspective. Nature. 408:433–439. 2000. View Article : Google Scholar : PubMed/NCBI
27.	Schar P: Spontaneous DNA damage, genome instability and cancer--when DNA replication escapes control. Cell. 104:329–332. 2001. View Article : Google Scholar : PubMed/NCBI
28.	Hoeijmakers JH: Genome maintenance mechanisms for preventing cancer. Nature. 411:366–374. 2001. View Article : Google Scholar : PubMed/NCBI
29.	Rouse J and Jackson SP: Interfaces between the detection, signaling and repair of DNA damage. Science. 297:547–551. 2002. View Article : Google Scholar : PubMed/NCBI
30.	Lee SW, Fang L, Igarashi M, Ouchi T, Lu KP and Aaronson SA: Sustained activation of Ras/Raf/mitogen-activated protein kinase cascade by the tumor suppressor p53. Proc Natl Acad Sci USA. 97:8302–8305. 2000. View Article : Google Scholar : PubMed/NCBI
31.	Tang J and Chu G: Xeroderma pigmentosum complementation group E and UV-damaged DNA-binding protein. DNA Repair. 1:601–616. 2002. View Article : Google Scholar : PubMed/NCBI
32.	Levine AJ and Oren M: The first 30 years of p53: growing ever more complex. Nat Rev Cancer. 9:749–758. 2009.PubMed/NCBI
33.	Toledo F and Wahl GM: Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer. 6:909–923. 2006. View Article : Google Scholar : PubMed/NCBI
34.	Riley T, Sontag E, Chen P and Levine A: Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol. 9:402–412. 2008. View Article : Google Scholar : PubMed/NCBI
35.	Chen Z, Trotman LC, Shaffer D, et al: Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature. 436:725–730. 2005. View Article : Google Scholar : PubMed/NCBI
36.	Fridman JS and Lowe SW: Control of apoptosis by p53. Oncogene. 22:9030–9040. 2003. View Article : Google Scholar : PubMed/NCBI
37.	Hoglund P: DNA damage and tumor surveillance: one trigger for two pathways. Sci STKE. 2006:pe22006.PubMed/NCBI
38.	Wang D and Lippard SJ: Cellular processing of platinum anti-cancer drugs. Nat Rev Drug Discov. 4:307–320. 2005. View Article : Google Scholar
39.	Abraham RT: Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev. 15:2177–2196. 2001. View Article : Google Scholar : PubMed/NCBI